Blood-based tests enable the detection of a wide range of exploratory and candidate pathophysiological biomarkers, reflecting the full spectrum of AD-driving molecular mechanisms beyond the conventional amyloid- and tau-based tests [80]. This evidence concerns the gene MAPT and Alzheimer disease.